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Summary Concentrations of plasma arginine vasopressin (AVP) were studied in patients receiving chemo-
therapy. Of the 18 patients studied, nine experienced nausea and vomiting and the remaining nine were non-
vomiters who suffered at worst mild nausea. Plasma AVP in the non-vomiting group remained within the
normal range (0.5-1.5pmoll-1) throughout the sampling period. However, patients who vomited showed
(with one exception) substantial rises in AVP ranging from 4 to 129-fold. Plasma AVP concentrations were
outside the normal range in vomiters and were higher than in non-vomiting patients at 3h (P<0.05) and 5h
(P<0.01) after chemotherapy. One patient was sampled during consecutive treatment courses, once as a
vomiter and once as a non-vomiter; results demonstrated a 16-fold rise in AVP as a vomiter and no rise as a
non-vomiter. Significant changes in plasma AVP levels were also observed in patients who suffered moderate
or severe nausea compared to those who had mild or no nausea (P<0.05). Plasma AVP may prove to be a
good objective marker for nausea in future anti-emetic trials.
Cytotoxic drugs used in the treatment of a range of malig-
nancies may produce severe gastrointestinal toxicity. This
may lead to refusal of curative therapy or to a decline in
palliative benefits offered by cytotoxic treatment. The exact
mechanisms of chemotherapy-induced nausea and vomiting
are poorly understood, and further exploration of this field
may contribute to achieving major emetic control in such
patients.
Cytotoxic drug-induced vomiting is thought to act via the
chemoreceptor trigger zone (CTZ) in the area postrema.
Afferent pathways then pass via the nucleus tractus solitarius
to the medullary vomiting (MVC) centre, the efferent com-
ponent of which includes connections with the nucleus
ambiguus and the dorsal motor nucleus of the vagus. Blood
borne emetics are thought to be 'chemosensed' by the CTZ
or to cause neurotransmitter release from afferent neurons
synapsing in the CTZ (Harris, 1982). A range of neurotrans-
mitters and peptides, including arginine vasopressin (AVP),
are excitatory to the neurons of the CTZ and may have
some role in provoking emesis (Carpenter &
Strominger, 1984). In addition direct stimulation of the
MVC via vagal afferents has been described (Grahame-
Smith, 1984). The dopamine agonist apomorphine (thought
to act via the CTZ) will induce nausea in most patients at
varying doses. In those patients experiencing nausea and
vomiting, substantial rises in plasma AVP are seen; this
occurs without significant changes in blood pressure or
plasma osmolality (Robertson, 1977). However, in patients
with diabetes insipidus, apomorphine-induced nausea and
vomiting is observed in the absence of any change in AVP
levels (Fisher et al., 1982). Fisher et al. reported on 11
patients receiving various cytotoxic drugs, of whom seven
had chemotherapy-induced emesis. Elevation in AVP levels
was observed in these patients before the onset of emesis,
with levels reaching a maximum approximately 1 h following
the onset of emesis. Plasma AVP levels did not rise in
patients who did not vomit. No patient received cisplatinum
or anti-emetics in this trial. This study was performed to
evaluate further the effect of nausea and vomiting on AVP
levels in patients receiving chemotherapy, including the
highly emetogenic cisplatinum, and to assess the effects of
anti-emetics on these levels.
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Patients and methods
Eighteen unselected patients receiving chemotherapy entered
the study. Patients with renal failure or inappropriate ADH
secretion were excluded. Informed consent was obtained
from all patients for serial blood sampling taken using a
Braunula sampling cannula. Blood samples (5ml) were taken
before chemotherapy and again at 1, 3 and 5h following
cytotoxic drug administration. Samples were drawn into
chilled syringes and transferred into chilled glass lithium
heparin tubes, centrifuged immediately at 4°C for 15min at
1,000g and stored at -70°C. Samples were analysed using a
radioimmunoassay (RIA) for vasopressin (Rooke & Baylis,
1982) (limit of detection 0.3pmoll-1; intra- and inter-assay
coefficient of variation 9.7 and 15.3% at lOpmoll-P respec-
tively). Blood samples for plasma osmolality and plasma
electrolytes were taken before chemotherapy. Blood pressure
was recorded at blood sampling times and during the
sampling period patients were asked to complete a self-
assessment form detailing nausea using a visual analogue
scale (10cm linear scale). The number of times each patient
vomited per time interval was recorded. Mild, moderate and
severe nausea were defined by subdividing the visual analo-
gue scale into three equal portions, the first third being equal
to mild nausea and the last to severe nausea.
Statistics
Non-parametric statistical tests (Kolmogorov-Smirnov) were
used to compare plasma AVP concentrations in vomiters to
non-vomiters, and patients with moderate or severe nausea
to those with mild or no nausea.
Results
Patient details are listed in Table I. The majority of patients
received cisplatinum, with all receiving potentially emeto-
genic drugs. As shown in Table I, no differences in blood
pressure, plasma osmolality, sodium levels or basal AVP
levels were detected between the two groups (P>0.05). Basal
levels were all within the normal range. Plasma AVP con-
centrations are shown in Figure la and b. The time at which
vomiting started is indicated by an arrow. Patients who
vomited during chemotherapy showed considerable increases
in plasma AVP in all but one instance, whereas all non-
vomiters had plasma AVP levels within the normal range
(0.5-1.5pmoll-1). Higher concentrations of plasma AVP
were detected in vomiting patients at 3h (5.2+9.0pmoll-1)
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Table I Patient details
Vomiters Non-vomiters
Mean age 44 (range 36-61) 37 (range 16-58)
Sex 6M: 3F 7M: 2F
Diagnosis 3 Lung 2 Sarcoma
2 Hodgkin's disease 2 Non-Hodgkin's-
lymphoma
1 Gastric 1 Oesophagus
1 Melanoma 1 Hodgkins disease
1 Adenocarcinoma UO 1 Lung
1 Ovary 1 Adenocarcinoma UO
I Teratoma
Cytotoxic
agent 5 Cisplatinum 6 Cisplatinum
2 Doxorubicin 2 Doxorubicin
1 Ifosfamide 1 Cyclophosphamide/Dox
1 DTIC
Anti-emetic 6 Domp+Dex 5 Domp+Dex
1 Domp+Chlorproma- 4 BRL 43694a and Dex
zine
1 BRL 43694a and Dex
1 Chlorpromazine and
Dex
Mean BP Before Before
(mmHg 98+15 92+12
s.d.)
After After
102+19 91±15 (n.s.)
Mean POsm 286+8.4 286.8±4.4 (n.s.)
(mos-mol
kg-1
+s.d.)
Mean PNa 138+1.7 138.6+2.5 (n.s.)
(mmoll
+s.d.)
aBRL 43694 is a new 5HT 3 receptor antagonist (Carmichael et
al., 1988).
Domp=Domperidone, Dex =Dexamethasone, Dox=Doxorubi-
cin.
n.s.=not significant, s.d.=standard deviation.
(P<0.05) and 5h (11.8+16.2pmoll-1) (P<0.01) post
chemotherapy. In vomiting patients maximum AVP con-
centrations (12.4+16.0pmoll-1) were higher than in
non-vomiting patients (P<0.01). In two instances plasma AVP
concentrations had risen markedly before the onset of vomit-
ing, but as blood sampling was intermittent, it was not
always possible to obtain a sample immediately before the
first vomiting episode. In one patient a plasma AVP value
within the normal range was found following a single vomit:
this represented a doubling of the basal value and the AVP
value was subsequently found to be further increased after
continued vomiting.
All results were standardised to basal levels. The plasma
AVP increases expressed as fold increases above basal values
were 0.33-129, (median 16) in vomiters and -1.3 to 1.5
(median -0.14) in non-vomiters. In one instance, studies
were carried out on one patient during two consecutive
treatment courses. The patient vomited following the first
course of treatment, but did not vomit during the second
course. These results show a 16-fold rise in AVP level with
the first course when the patient vomited, but no rise during
the second course (Table II).
Relative increases in AVP levels were greater in patients
who experienced moderate or severe nausea compared to
those with mild or no nausea (P<0.05). Of eight patients
who experienced moderate or severe nausea, seven had
significant increases in plasma AVP levels (median 7.2, range
0.4-52pmoll-1). This represented increases of 1.3-129-fold
above pre-treatment levels. The other patient who did not
show an increase was the one patient in whom the AVP level
did not increase following vomiting. Ten patients experienced
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Figure 1 The plasma AVP concentrations (pmoll-') in (a)
vomiters and (b) non-vomiters during chemotherapy. Normal
range of AVP levels for this study was taken as 0.5-1.5pmoll-1.
The arrows in (a) indicate the time at which vomiting
commenced.
Table II Patient E.S. as vomiter and non-vomiter
Vomiter Non-vomiter
Plasma AVP (pmolI-1)
Time (h)
0
+1
+3
+5
Mean arterial pressure (mmHg)
Time (h)
0
+1
+3
+5
Plasma osmolality (mosmolkg-1)
Plasma sodium (mmoll-1)
Fold increase in plasma AVP
0.3
0.3
2.0
5.1
83
83
93
73
276
139
16
0.3
0.3
0.3
0.3
96
93
90
73
292
138
No rise
l1no or only mild nausea, and of these only one showed a
significant increase in AVP levels (median 0.65, range 0.3-
5.6pmoll-1). These values represented increases of 0-5-fold
above pre-treatment values. The one patient with mild
nausea who showed an increase in AVP levels also vomited.
Nausea was absent or mild in all of the non-vomiters, and
none of these had elevation of AVP levels. In view of the
close association of moderate or severe nausea with vomit-
ing, it is unclear whether plasma AVP levels would act as a
marker for severe chemotherapy induced nausea alone.
Discussion
The results of the present study demonstrate rises in plasma
AVP in patients with cytotoxic drug-induced vomiting. This
confirms the results previously reported on 11 patients who
received a variety of cytotoxic drugs (Fisher et al., 1982). In
our study, elevation of AVP levels was observed following
cisplatinum chemotherapy and these increases occurred
despite the use of various anti-emetics. The degree of
elevation in plasma AVP levels in this study was lower than
that observed with apomorphine induced nausea and vomit-
ing (Robertson, 1977), although the increases were similar to
those described following chemotherapy-induced emesis
(Fisher et al., 1982). However, patients in this study, of
necessity, received anti-emetic drugs before and during the
sampling period. Metoclopramide was not included in any of
the anti-emetic regimens as it has been shown to facilitate a
small 2-fold rise in plasma AVP with a peak at 20min post
metoclopramide administration. Haloperidol and domperi-
done do not demonstrate this effect (Norbiato et al., 1986).
Given the comparable blood pressure, plasma osmolality,
electrolytes and basal AVP level in each group, there appears
to be two possible explanations to account for this rise in
plasma AVP; one that AVP itself forms a link in the
sequential mechanism for emesis, the other that AVP rises in
response to vomiting. Certainly AVP levels continued to rise
following the onset of vomiting, as was described in the
study of Fisher et al. (1982), which could suggest that levels
may increase in response to vomiting. However, in two cases
described in this study, elevations in AVP levels were
observed before the onset of emesis. On the other hand, we
know that nausea and vomiting occur in patients with
diabetes insipidus treated with apomorphine in the absence
of any change in AVP levels (Nussey et al., 1988). In
addition, patients treated with ipecacuahna did not exhibit
changes in AVP levels despite symptoms of nausea and
emesis similar to that following apomorphine, where large
increases in AVP were observed (Nussey et al., 1988).
However, it should be remembered that for such a sophisti-
cated reflex it is likely that there are many pathways
involved. Therefore, the results do not exclude AVP from a
mediating role in the pathogenesis of chemotherapy-induced
emesis. From this study, we are unable to determine the
relative role of nausea and vomiting independently on the
AVP response, as frequent blood sampling would be
necessary to estimate the exact rate and timing of the
increase in plasma AVP.
There is debate as to whether AVP infusions can cause
emesis. Williams et al. (1986) reported no emesis in patients
receiving up to 75pmolmin-1 kg-1 AVP as a continuous
infusion, where plasma levels of 3890pmol 1- were
observed, significantly higher than the levels observed in this
study. In contrast, Thomford & Sirinek (1975) reported
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significant emesis in cirrhotic patients treated with bolus or
infusional doses of vasopressin up to 40 units, although
plasma levels were not performed in this study. Whether
cirrhosis per se affected the gastrointestinal response to AVP
remains a matter for conjecture. Therefore, AVP may not, in
itself, be sufficient to induce emesis in normal subjects.
However, AVP could act with other stimuli to produce a
summed input to or from the MVC. Recently a sequential
activation model has been suggested for control of the
vomiting response (Davis et al., 1984). This describes the
MVC as an integrator of several effector nuclei responsible
for the autonomic and somatic components of nausea and
vomiting. It is conceivable that AVP may form a link in this
cascade. AVP rise may then be a final step in a sequential
pathway for chemotherapy-induced emesis. It is thought that
AVP secretion is modulated by dopamine and opioid pep-
tides, although there is some debate as to their excitatory or
inhibitory effects (Weitzman et al., 1977; Carter & Lightman,
1985). Both these neurotransmitters are considered important
causative factors in chemotherapy-induced vomiting (Harris,
1982) and AVP itself has been shown to be excitatory to the
neurons of the CTZ (Carpenter & Strominger, 1984).
If AVP is a mediator of cytotoxic drug induced emesis, the
rate of change in AVP levels may be as important as the
degree of rise. From the present data two patients demon-
strated elevated AVP concentrations of 28 and 5.6pmoll-1
before the onset of vomiting, compatible with a causative
influence of AVP rise or potentially as an indicator of
nausea. Furthermore, the results of the other seven patients
who vomited do not exclude the possibility that a rapid
increase in plasma AVP may have preceded the onset of
emesis. Certainly, these data suggest that increases in AVP
levels may be associated with nausea in these patients.
Shelton et al. (1977) previously reported an association
between nausea and elevation in AVP levels, and the find-
ings of this study give tentative support to this hypothesis.
AVP may have a role in affecting conditioned responses to
chemotherapy separately from emetogenic episodes, and this
could be assessed by detailed follow-up and evaluation of
longer term studies.
Elevation of J-endorphin levels has been associated with
increases in AVP levels and could represent another media-
tor of emesis in these patients. Interestingly, dexamethasone
has been shown to lower the levels of /-endorphin in
postoperative patients (Hargreaves et al., 1987), and likewise
steroids have been shown to reduce AVP levels (Martin,
1985). Dexamethasone is an effective anti-emetic although its
mode of action remains far from clear. It is possible that the
reduction of AVP and #-endorphin levels could be important
in this activity. Further analysis of a possible dexamethasone
suppression effect would be useful. In the present study the
one vomiter who did not receive dexamethasone showed the
highest increase in AVP, 129-fold.
Should AVP levels correlate well with the severity of
nausea, measurement of these levels could prove to be a
valuable objective marker in the assessment of the effective-
ness of new anti-emetic drugs. Currently, in many anti-
emetic studies nausea is assessed subjectively using linear
visual analogue scores, and it would be of great value in the
interpretation of these studies if there was an objective
marker. More detailed information is required to evaluate
this hypothesis. In particular, more frequent blood sampling
is required in an attempt to distinguish the effects of nausea
from those of vomiting, and to correlate the degree of
elevation of the AVP levels with the severity of the nausea.
These studies are currently underway in our department.
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